Pierre‐Luc Boudreault

This study develops and evaluates crystal-engineered ligands (CBs) for targeting treatment-resistant androgen receptors in prostate cancer, showing their potential as novel therapeutic agents.

The paper identifies β-Klotho as a novel substrate of TMPRSS6, showing that TMPRSS6 cleavage reduces KLB surface abundance and attenuates FGF19 signaling, linking TMPRSS6 to hepatic lipid metabolism.

This paper describes a pepducin derived from NTS1 that acts as a biased allosteric modulator, preferentially activating G proteins over β-arrestin and inhibiting receptor internalization.

The paper evaluates the antibacterial activity of tomatidine analogs against various bacterial strains, identifying TM-184 as effective against Gram-positive, Gram-negative, and multidrug-resistant bacteria, with in vivo efficacy in a mouse model.

This study identifies AngII analogs with modified C-terminal peptides that selectively engage Gq or β-arrestin pathways, showing differential effects on cardiac function and blood pressure in rats.

The paper determines the structural basis of TMPRSS11D autocleavage activation and shows that nafamostat mesylate is cleaved by TMPRSS11D, reducing its efficacy as a protease inhibitor.

This study identifies low nanomolar TMPRSS13 inhibitors through chemical library screening and molecular modeling, showing their ability to block SARS-CoV-2 pseudovirus entry.